Skip to main content
Log in

Improving Medication Dosing in the Obese Patient

  • Current Opinion
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

The purpose of this paper is to provide clinicians with important considerations and caveats when evaluating published literature on medication dosing in obese subjects, since much of this literature involves short-term pharmacokinetic or pharmacodynamic studies that are not designed to look at clinically important outcomes. A secondary objective is to suggest improvements in the reporting of dosing information derived from clinical studies and incorporated into product information labeling that should help clinicians design medication-specific dosing regimens for patients with obesity. Data sources included published studies, review papers, and clinical practice guidelines concerning drug dosing of subjects with obesity. Medication dosing recommendations in product labeling typically are derived from studies of normal healthy volunteers and patients with single-system disease states or patients in a specialized setting (e.g. operating room, intensive care unit). Even in studies with relatively large sample sizes there are often relatively few subjects with extremes of body composition such as patients with a body mass index (BMI) greater than 40 kg/m2, so the appropriateness of labeled dosing information for these subjects is particularly ill-defined. Investigations of medication labeling information have demonstrated the inadequacy of this information for dosing patients of more extreme body size. Clinical investigations of drugs should be designed and the results reported in a manner that allows for meaningful recommendations for drug dosing in patients with varying degrees of obesity. Until and when such studies are routinely performed, there are steps that can be taken by the pharmaceutical industry, clinicians, and governmental agencies to help insure optimal drug dosing in obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Centers for Disease Control and Prevention: Data, Trends and Maps. Available online at: http://www.cdc.gov/obesity/data/prevalence-maps.html. Accessed 13 Jan 2016.

  3. Centers for Disease Control and Prevention: NCHS Health E-Stat. Available online at: http://www.cdc.gov/nchs/data/hestat/obesity_adult_09_10/obesity_adult_09_10.htm. Accessed 13 Jan 2016.

  4. Godoy R, Goodman E, Levins R, Leonard WR. Anthropometric variability in the USA: 1971–2002. Ann Hum Biol. 2005;32:469–86.

    Article  CAS  PubMed  Google Scholar 

  5. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer and service-specific estimates. Health Aff. 2009;28:w822–31.

    Article  Google Scholar 

  6. Grieve E, Fenwick E, Yang H-C, Lean M. The disproportionate economic burden associated with severe and complicated obesity: a systematic review. Obesity Rev. 2013;14:883–94.

    Article  CAS  Google Scholar 

  7. Van Lancker P1, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia 2011;66:721–5.

  8. van Kralingen S, van de Garde EM, Knibbe CA, Diepstraten J, Wiezer MJ, van Ramshorst B, van Dongen EP. Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients. Br J Clin Pharmacol 2011;71:34–40.

  9. Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg 2011;113:57–62.

  10. Bioelectric impedance analysis in body composition measurement. National institutes of health technology assessment conference statement. Am J Clin Nutr. 1996;64(suppl):524S–32S.

    Google Scholar 

  11. Gray DS, Bray GA, Gemayel N, et al. Effect of obesity on bioelectrical impedance. Am J Clin Nutr. 1989;50:255–60.

    CAS  PubMed  Google Scholar 

  12. Zarowitz BJ. Bioelectrical impedance analysis measurements for drug pharmacokinetics. Am J Clin Nutr. 1996;64(suppl):519S–23S.

    CAS  PubMed  Google Scholar 

  13. Thibault R, Genton L, Pichard C. Body composition: why, when and for who? Clin Nutr. 2012;31:435–47.

    Article  PubMed  Google Scholar 

  14. Coppini LZ, Waitzberg DL, Campos AC. Limitations and validation of bioelectrical impedance analysis in morbidly obese patients. Curr Opin Clin Nutr Metab Care. 2005;8:329–32.

    Article  PubMed  Google Scholar 

  15. Ismael S, Savalle M, Trivin C, Gillaizeau F, D’Auzac C, Faisy C. The consequences of sudden fluid shifts on body composition in critically ill patients. Crit Care. 2014;18:R49.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health-Syst Pharm. 2009;66:642–8.

    Article  CAS  PubMed  Google Scholar 

  17. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–33.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Pai MP, Nafziger AM, Bertino JS. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011;55:4006–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54:621–5.

    Article  CAS  PubMed  Google Scholar 

  20. Alexander JK, Dennis EW, Smight WG, et al. Blood volume, cardiac output, and distribution of systemic blood flow in obesity. Cardiovasc Res Centr Bull. 1963;962:39–44.

    Google Scholar 

  21. Manzone TA, Dam HQ, Soltis D, Sagar VV. Blood volume analysis: a new technique and new clinical interest reinvigorate a classic study. J Nucl Med Technol. 2007;35:55–63.

    Article  PubMed  Google Scholar 

  22. Anastasio P, Spitali L, Frangiosa A, et al. Glomerular filtration in severely overweight normotensive humans. Am J Kidney Dis. 2000;35:1144–8.

    Article  CAS  PubMed  Google Scholar 

  23. Lemoine S, Guebre-Egziabher F, Sens F, et al. Accuracy of GFR estimation in obese patients. Clin J Am Soc Nephrol. 2014;9:720–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304.

    Article  CAS  PubMed  Google Scholar 

  25. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size. Clin Pharmacokinet. 2012;51:319–30.

    Article  CAS  PubMed  Google Scholar 

  26. Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: towards evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149–67.

    Article  CAS  PubMed  Google Scholar 

  27. Gibney MA, Aree CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26:1519–30.

    Article  CAS  PubMed  Google Scholar 

  28. Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26:1663–78.

    Article  PubMed  Google Scholar 

  29. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and non-obese NIDDM patients. Diab Care. 1995;18:986–91.

    Article  CAS  Google Scholar 

  30. Gagnon-Auger M, Du Souich P, Baillargeon JP, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with Type 2 diabetes. Diab Care. 2010;33:2502–7.

    Article  CAS  Google Scholar 

  31. Hogan QH, Prost R, Kulier A, Taylor ML, Liu S, Mark L. Magnetic resonance imaging of cerebrospinal fluid volume and the influence of body habitus and abdominal pressure. Anesthesiology. 1996;84:1341–9.

    Article  CAS  PubMed  Google Scholar 

  32. Carvalho B, Collins J, Drover DR, Ralls LA, Riley ET. ED50 and ED95 of intrathecal bupivacaine in morbidly obese patients undergoing Cesarean delivery. Anesthesiology. 2011;114:529–35.

    Article  CAS  PubMed  Google Scholar 

  33. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90:77–89.

    Article  CAS  PubMed  Google Scholar 

  34. Jacques KA, Erstad BL. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health-Syst Pharm. 2010;67:1948–50.

    Article  PubMed  Google Scholar 

  35. Harskamp-van Ginkel MW, Hill KD, Becker K, et al. Drug dosing and pharmacokinetics in children with obesity: a systematic review. JAMA Pediatr. 2015;169:678–85.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Practice Guidelines. J Clin Oncol. 2012;30:1553–61.

    Article  PubMed  Google Scholar 

  37. Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. Biol Blood Marrow Transplant. 2014;20:600–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian L. Erstad.

Ethics declarations

Conflict of interest

No conflicts of interest for the author.

Funding

No funding was obtained.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erstad, B.L. Improving Medication Dosing in the Obese Patient. Clin Drug Investig 37, 1–6 (2017). https://doi.org/10.1007/s40261-016-0461-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-016-0461-4

Keywords

Navigation